Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/85959 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.85959 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.859592023-06-19T00:52:10Z Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV Ogbe A. Mahidol University Medicine Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. 2023-06-18T17:52:10Z 2023-06-18T17:52:10Z 2022-04-08 Article JCI Insight Vol.7 No.7 (2022) 10.1172/jci.insight.157031 23793708 35192543 2-s2.0-85128131875 https://repository.li.mahidol.ac.th/handle/123456789/85959 SCOPUS |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Ogbe A. Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
description |
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. |
author2 |
Mahidol University |
author_facet |
Mahidol University Ogbe A. |
format |
Article |
author |
Ogbe A. |
author_sort |
Ogbe A. |
title |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
title_short |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
title_full |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
title_fullStr |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
title_full_unstemmed |
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV |
title_sort |
durability of chadox1 ncov-19 vaccination in people living with hiv |
publishDate |
2023 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/85959 |
_version_ |
1781416236509298688 |